Jeri Matera

10.4k total citations · 5 hit papers
16 papers, 8.1k citations indexed

About

Jeri Matera is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeri Matera has authored 16 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeri Matera's work include Cancer Cells and Metastasis (14 papers), Cancer Genomics and Diagnostics (9 papers) and Metastasis and carcinoma case studies (4 papers). Jeri Matera is often cited by papers focused on Cancer Cells and Metastasis (14 papers), Cancer Genomics and Diagnostics (9 papers) and Metastasis and carcinoma case studies (4 papers). Jeri Matera collaborates with scholars based in United States, Spain and India. Jeri Matera's co-authors include Michael Craig Miller, Leon W.M.M. Terstappen, W. Jeffrey Allard, Gerald V. Doyle, Massimo Cristofanilli, Daniel F. Hayes, G. Thomas Budd, Alison Stopeck, Matthew J. Ellis and James M. Reuben and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Jeri Matera

16 papers receiving 7.9k citations

Hit Papers

Circulating Tumor Cells, Disease Progression, and Surviva... 2004 2026 2011 2018 2004 2004 2005 2006 2006 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
    2004 3.5k citations Massimo Cristofanilli, G. Thomas Budd et al. New England Journal of Medicine profile →
  2. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases
    2004 2.0k citations W. Jeffrey Allard, Jeri Matera et al. Clinical Cancer Research profile →
  3. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
    2005 857 citations Massimo Cristofanilli, Daniel F. Hayes et al. Journal of Clinical Oncology profile →
  4. Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival
    2006 808 citations Daniel F. Hayes, Massimo Cristofanilli et al. Clinical Cancer Research profile →
  5. Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
    2006 594 citations G. Thomas Budd, Massimo Cristofanilli et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeri Matera United States 9 6.3k 4.3k 2.2k 2.1k 1.6k 16 8.1k
Gerald V. Doyle United States 24 9.6k 1.5× 6.8k 1.6× 3.7k 1.7× 2.9k 1.4× 2.5k 1.5× 39 12.4k
Sunitha Nagrath United States 39 4.6k 0.7× 3.2k 0.7× 1.5k 0.7× 4.5k 2.2× 3.0k 1.9× 107 9.4k
Shannon L. Stott United States 31 4.9k 0.8× 3.1k 0.7× 1.1k 0.5× 3.2k 1.6× 2.6k 1.6× 62 8.3k
Catherine Alix‐Panabières France 48 7.6k 1.2× 6.8k 1.6× 2.7k 1.2× 2.4k 1.2× 3.8k 2.4× 152 11.8k
François‐Clément Bidard France 47 5.0k 0.8× 4.5k 1.1× 2.4k 1.1× 945 0.5× 2.0k 1.3× 220 7.8k
Matthew Krebs United Kingdom 28 4.0k 0.6× 2.2k 0.5× 1.9k 0.8× 796 0.4× 1.4k 0.9× 156 5.4k
H. Tissing Netherlands 7 3.1k 0.5× 2.1k 0.5× 1.4k 0.6× 795 0.4× 632 0.4× 10 4.0k
Nicola Aceto Switzerland 32 4.3k 0.7× 2.7k 0.6× 912 0.4× 1.5k 0.7× 2.7k 1.7× 69 7.0k
Steven J. Cohen United States 40 5.0k 0.8× 2.1k 0.5× 1.8k 0.8× 631 0.3× 1.2k 0.7× 174 6.6k
Paula D. Ryan United States 21 3.0k 0.5× 1.6k 0.4× 799 0.4× 1.8k 0.9× 1.5k 1.0× 48 5.2k

Countries citing papers authored by Jeri Matera

Since Specialization
Citations

This map shows the geographic impact of Jeri Matera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeri Matera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeri Matera more than expected).

Fields of papers citing papers by Jeri Matera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeri Matera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeri Matera. The network helps show where Jeri Matera may publish in the future.

Co-authorship network of co-authors of Jeri Matera

This figure shows the co-authorship network connecting the top 25 collaborators of Jeri Matera. A scholar is included among the top collaborators of Jeri Matera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeri Matera. Jeri Matera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Baselga, José, Alexey Manikhas, Javier Cortés, et al.. (2014). Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Annals of Oncology. 25(3). 592–598. 75 indexed citations
2.
Peña, Lorena de la, Javier Cortés, Alexey Manikhas, et al.. (2013). Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology. 31(15_suppl). 517–517. 3 indexed citations
3.
Budd, G. Thomas, Massimo Cristofanilli, Mathew J. Ellis, et al.. (2006). Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer. Clinical Cancer Research. 12(21). 6403–6409. 594 indexed citations breakdown →
4.
Hayes, Daniel F., Massimo Cristofanilli, G. Thomas Budd, et al.. (2006). Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. Clinical Cancer Research. 12(14). 4218–4224. 808 indexed citations breakdown →
5.
Cohen, Steven J., Leon W.M.M. Terstappen, Cornelis J.A. Punt, et al.. (2006). Circulating endothelial cells (CEC) and circulating tumor cells (CTC) in patients (pts) with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 24(18_suppl). 3531–3531. 3 indexed citations
6.
Cristofanilli, Massimo, Daniel F. Hayes, G. Thomas Budd, et al.. (2005). Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer. Journal of Clinical Oncology. 23(7). 1420–1430. 857 indexed citations breakdown →
7.
Stopeck, A., Massimo Cristofanilli, G. Thomas Budd, et al.. (2005). Circulating tumor cells - not serum tumor markers - predict survival in metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 9516–9516. 5 indexed citations
8.
Cristofanilli, Massimo, G. T. Budd, Matthew J. Ellis, et al.. (2005). Presence of circulating tumor cells (CTC) in metastatic breast cancer (MBC) predicts rapid progression and poor prognosis. Journal of Clinical Oncology. 23(16_suppl). 524–524. 8 indexed citations
9.
Hayes, Daniel F., G. Thomas Budd, Mathew J. Ellis, et al.. (2005). Cristofanilli M, Hayes DF, Budd GT et al.Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-30. 2 indexed citations
10.
Budd, G. T., Massimo Cristofanilli, Matthew J. Ellis, et al.. (2005). Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 503–503. 10 indexed citations
11.
Allard, W. Jeffrey, Jeri Matera, Michael Craig Miller, et al.. (2004). Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases. Clinical Cancer Research. 10(20). 6897–6904. 2015 indexed citations breakdown →
12.
Cristofanilli, Massimo, G. Thomas Budd, Matthew J. Ellis, et al.. (2004). Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England Journal of Medicine. 351(8). 781–791. 3546 indexed citations breakdown →
13.
Allard, W. Jeffrey, Jeri Matera, Michael Craig Miller, et al.. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Journal of Clinical Oncology. 22(14_suppl). 9552–9552. 32 indexed citations
14.
Allard, W. Jeffrey, Jeri Matera, Michael Craig Miller, et al.. (2004). Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Journal of Clinical Oncology. 22(14_suppl). 9552–9552. 101 indexed citations
15.
Hayes, Daniel F., Massimo Cristofanilli, G. Thomas Budd, et al.. (2004). Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria. Journal of Clinical Oncology. 22(14_suppl). 509–509. 6 indexed citations
16.
Hayes, Daniel F., G. T. Budd, A. Stopeck, et al.. (2004). Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): A prospective, multi-institutional tria. Journal of Clinical Oncology. 22(14_suppl). 509–509. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerald V. Doyle Breakdown of academic impact, for papers by Sunitha Nagrath Breakdown of academic impact, for papers by Shannon L. Stott Breakdown of academic impact, for papers by Catherine Alix‐Panabières Breakdown of academic impact, for papers by François‐Clément Bidard Breakdown of academic impact, for papers by Matthew Krebs Breakdown of academic impact, for papers by H. Tissing Breakdown of academic impact, for papers by Nicola Aceto Breakdown of academic impact, for papers by Steven J. Cohen Breakdown of academic impact, for papers by Paula D. Ryan
Rankless by CCL
2026